A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants

Vaccine

Volumn 32, Issue 40, 2014, Pages 5206-5211

  Martinon Torres, Federico ^a   Gimenez Sanchez, Francisco ^b   Bernaola Iturbe, Enrique ^c   Diez Domingo, Javier ^d,e   Jiang, Qin ^f   Perez, John L ^f  

^a University Hospital of Santiago de Compostela   (Spain)

^b HOSPITAL TORRECÁRDENAS   (Spain)

^c Instituto de Investigación Sanitaria de Navarra   (Spain)

^d Centro Superior de Investigacion en Salud Publica CSISP   (Spain)

^e Santiago University Clinical Hospital   (Spain)

^f Pfizer Vaccines   (United States)

Author keywords

Factor H binding protein; Infants; LP2086; Neisseria meningitidis serogroup B

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; LIPOPROTEIN; MENINGOCOCCUS VACCINE; NEIS VAC; PNEUMOCOCCUS VACCINE; RLP 2086; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; RECOMBINANT VACCINE;

ARTICLE; ASEPTIC MENINGITIS; ASTHMA; CLINICAL STUDY; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECREASED APPETITE; DERMATITIS; DOSE RESPONSE; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; MALE; MENINGOCOCCOSIS; MULTICENTER STUDY; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZATION; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLEEP DISORDER; URINARY TRACT INFECTION; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION; VIRUS INFECTION; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; CLINICAL TRIAL; EARLY TERMINATION OF CLINICAL TRIAL; FEVER; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FEVER; HUMANS; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; SINGLE-BLIND METHOD; VACCINES, SYNTHETIC;

EID: 84906057412     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.049     Document Type: Article

References (21)

1. McNeil L.K., Zagursky R., Shuo L., Murphy E., Zlotnick G., Hoiseth S.K., et al. The role of factor H-binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev 2013, 77:234-252.
2. Health Protection Agency. Meningococcal Reference Unit isolates of Neisseria menengitidis: England and Wales, by serogroup & epidemiological year, 1998/99-2009/10. Available at: [accessed 16.10.13]. http://www.hpa.org.uk/web/HPAweb%26HPAwebStandard/HPAweb_C/1234859711901.
3. Cohn A.C., MacNeil J.R., Harrison L.H., Hatcher C., Theodore J., Schmidt M., et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010, 50:184-191.
4. Racloz V.N., Luiz S.J. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 2010, 10:175.
5. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72:2088-2100.
6. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H-binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200:379-389.
7. Lucidarme J., Tan L., Exley R.M., Findlow J., Borrow R., Tang C.M. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H-binding protein. Clin Vaccine Immunol 2011, 18:1002-1014.
8. Kelly A., Jacobsson S., Hussain S., Olcen P., Molling P. Gene variability and degree of expression of vaccine candidate factor H-binding protein in clinical isolates of Neisseria meningitidis. APMIS 2013, 121:56-63.
9. Jiang H.Q., Hoiseth S.K., Harris S.L., McNeil L.K., Zhu D., Tan C., et al. Broad vaccine coverage predicted for a bivalent recombinant factor H-binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010, 28:6086-6093.
10. Richmond P.C., Marshall H.S., Nissen M.D., Jiang Q., Jansen K.U., Garces-Sanchez M., et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12:597-607.
11. Nissen M.D., Marshall H.S., Richmond P.C., Jiang Q., Harris S.L., Jones T.R., et al. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 2012, 32:364-371.
12. Richmond P.C., Nissen M.D., Marshall H.S., Lambert S.B., Roberton D., Gruber W.C., et al. A bivalent Neisseria meningitidis recombinant lipidated factor H-binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine 2012, 30:6163-6174.
13. Marshall H.S., Richmond P.C., Nissen M.D., Wouters A., Baber J., Jiang Q., et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013, 31:1569-1575.
14. Sheldon E., Schwartz H., Jiang Q., Giardina P.C., Perez J.L. A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults. Hum Vaccin Immunother 2012, 8:888-895.
15. Marshall H.S., Richmond P.C., Nissen M.D., Jiang Q., Anderson A.S., Jansen K.U., et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J 2012, 31:1061-1068.
16. Gossger N., Snape M.D., Yu L.M., Finn A., Bona G., Esposito S., et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012, 307:573-582.
17. Vesikari T., Esposito S., Prymula R., Ypma E., Kohl I., Toneatto D., et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013, 381:825-835.
18. Wong S.H., Lennon D.R., Jackson C.M., Stewart J.M., Reid S., Ypma E., et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J 2009, 28:385-390.
19. Oster P., O'Hallahan J., Aaberge I., Tilman S., Ypma E., Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007, 25:3075-3079.
20. Crockett M. Physiology of the neonatal immune system. J Obstet Gynecol Neonatal Nurs 1995, 24:627-634.
21. Petrova A., Mehta R. Dysfunction of innate immunity and associated pathology in neonates. Indian J Pediatr 2007, 74:185-191.